Skip to main content

Table 2 Characteristics of patients with complete/partial or no remission at First Follow-up

From: Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy

Characteristic

n = 32

Remissions

n = 23

P-value

Age (years)

39.5 ± 8.2

36.9 ± 7.7

0.24

Female sex, n (%)

23 (71.9%)

8 (34.8%)

0.01

Diabetes mellitus

4 (12.5%)

0 (0.0%)

0.22

Previous immunosuppressantsa

28 (87.5%)

20 (87.0%)

1.0

Receiving immunosuppressants at baselinea

23 (71.9%)

13 (56.5%)

0.37

Receiving TW at baselinea

16 (50.0%)

4 (17.4%)

0.03

Receiving RASi at baseline

27 (84.4%)

23 (100.0%)

0.13

Proteinuria (g/24 h)

2.4 (1.9, 3.5)

1.8 (1.5, 2.3)

0.01

Mean artery pressure at baseline (mmHg)

96.8 ± 11.0

91.0 ± 9.2

0.05

estimated GFR (ml/min per 1.73 m2)

63 ± 13

68 ± 11

0.14

eGFR < 60 ml/min per 1.73 m2

15 (46.9)

6 (26.1)

0.20

Serum albumin (g/dl)

39.6 (3.5)

41.7 (3.3)

0.03

KuXian Dosage (ug)

102 ± 24

100 ± 26

0.71

  1. TW tripterygium Wilfordii multiglycoside (the second generation of TwHF preparations), RASi Renin-angiotensin system inhibitors; a TW is also considered as an immunosuppressant